Nuvation Bio Inc
NUVB
查看详细走势图
5.700USD
+0.085+1.51%
收盘 02/06, 16:00（美东）报价延迟15分钟
1.95B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.51%
5天
+8.78%
1月
-35.52%
6月
+143.59%
今年开始到现在
-36.38%
1年
+139.50%
查看详细走势图
TradingKey Nuvation Bio Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Nuvation Bio Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名105/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价11.40。中期看，股价处于上升通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Nuvation Bio Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Nuvation Bio Inc亮点
亮点风险
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
业绩增长期
公司处于发展阶段，最新年度总收入7.87M美元
利润高增长
公司净利润处于行业前列，最新年度总收入7.87M美元
估值低估
公司最新PE估值-11.45，处于3年历史低位
机构减仓
最新机构持股226.59M股，环比减少14.00%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值353.69K
活跃度降低
近期活跃度降低，过去20天平均换手率0.61
分析师目标
根据
11
位分析师
买入
评级
11.400
目标均价
+94.54%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Nuvation Bio Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Nuvation Bio Inc简介
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
公司代码NUVB
公司Nuvation Bio Inc
CEOHung (David T)
网址https://www.nuvationbio.com/
相关品种
